{"transactions":[{"id":685791,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:57:29.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":800,"price":119.1688,"value":95335.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $118.73 to $119.52 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2295,"source":{"system":"sec-edgar","filing":"0001649904-26-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000164990426000013/form4.xml","form_type":"4"}},{"id":685790,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:57:29.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":3400,"price":118.2843,"value":402166.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $117.73 to $118.71 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3095,"source":{"system":"sec-edgar","filing":"0001649904-26-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000164990426000013/form4.xml","form_type":"4"}},{"id":685789,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:57:29.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":1556,"price":117.0759,"value":182170.1004,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.72 to $117.66 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6495,"source":{"system":"sec-edgar","filing":"0001649904-26-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000164990426000013/form4.xml","form_type":"4"}},{"id":685788,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:57:29.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":2007,"price":116.1093,"value":233031.3651,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.67 to $116.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8051,"source":{"system":"sec-edgar","filing":"0001649904-26-000013","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000164990426000013/form4.xml","form_type":"4"}},{"id":718606,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-02T20:52:49.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":4445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date."}],"balance_after":8888,"derivative":{"underlying":"Common Stock","underlying_shares":4445},"source":{"system":"sec-edgar","filing":"0001104659-26-080397","document":"tm2619643-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926080397/tm2619643-1_4seq1.xml","form_type":"4"}},{"id":718605,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:52:49.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2150,"price":110.41,"value":237381.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein."}],"balance_after":10058,"source":{"system":"sec-edgar","filing":"0001104659-26-080397","document":"tm2619643-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926080397/tm2619643-1_4seq1.xml","form_type":"4"}},{"id":718604,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:52:49.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":4445,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":12208,"source":{"system":"sec-edgar","filing":"0001104659-26-080397","document":"tm2619643-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926080397/tm2619643-1_4seq1.xml","form_type":"4"}},{"id":905439,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-02-13T22:47:38.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":25000,"derivative":{"exercise_price":98.47,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-26-015397","document":"tm266366-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926015397/tm266366-2_4seq1.xml","form_type":"4"}},{"id":905438,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T22:47:38.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":16650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date."}],"balance_after":16650,"derivative":{"underlying":"Common Stock","underlying_shares":16650},"source":{"system":"sec-edgar","filing":"0001104659-26-015397","document":"tm266366-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926015397/tm266366-2_4seq1.xml","form_type":"4"}},{"id":922320,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:31:57.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":6663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date."}],"balance_after":19987,"derivative":{"underlying":"Common Stock","underlying_shares":6663},"source":{"system":"sec-edgar","filing":"0001104659-26-009764","document":"tm264963-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926009764/tm264963-2_4seq1.xml","form_type":"4"}},{"id":922319,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:31:57.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2026,"price":108.99,"value":220813.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein."}],"balance_after":7763,"source":{"system":"sec-edgar","filing":"0001104659-26-009764","document":"tm264963-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926009764/tm264963-2_4seq1.xml","form_type":"4"}},{"id":922318,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-03T21:31:57.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":6663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":9789,"source":{"system":"sec-edgar","filing":"0001104659-26-009764","document":"tm264963-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465926009764/tm264963-2_4seq1.xml","form_type":"4"}},{"id":1092847,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-03T21:12:03.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":false,"shares":4445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date."}],"balance_after":13333,"derivative":{"underlying":"Common Stock","underlying_shares":4445},"source":{"system":"sec-edgar","filing":"0001104659-25-065844","document":"tm2519881-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465925065844/tm2519881-1_4seq1.xml","form_type":"4"}},{"id":1092846,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-03T21:12:03.000Z","date":"2025-07-02","kind":"sale","planned":true,"acquired":false,"shares":6,"price":64.6,"value":387.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on June 25, 2024 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":3126,"source":{"system":"sec-edgar","filing":"0001104659-25-065844","document":"tm2519881-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465925065844/tm2519881-1_4seq1.xml","form_type":"4"}},{"id":1092845,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-03T21:12:03.000Z","date":"2025-07-02","kind":"sale","planned":true,"acquired":false,"shares":1313,"price":64.81,"value":85095.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on June 25, 2024 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":3132,"source":{"system":"sec-edgar","filing":"0001104659-25-065844","document":"tm2519881-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465925065844/tm2519881-1_4seq1.xml","form_type":"4"}},{"id":1092844,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-03T21:12:03.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":true,"shares":4445,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":4445,"source":{"system":"sec-edgar","filing":"0001104659-25-065844","document":"tm2519881-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465925065844/tm2519881-1_4seq1.xml","form_type":"4"}},{"id":1260721,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-20T02:44:28.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after February 14, 2025, such that the option shall be fully vested and exercisable on February 14, 2029."}],"balance_after":40000,"derivative":{"exercise_price":56.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-25-015318","document":"tm257103-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465925015318/tm257103-2_4seq1.xml","form_type":"4"}},{"id":1260720,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T02:44:28.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":26650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date."}],"balance_after":26650,"derivative":{"underlying":"Common Stock","underlying_shares":26650},"source":{"system":"sec-edgar","filing":"0001104659-25-015318","document":"tm257103-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465925015318/tm257103-2_4seq1.xml","form_type":"4"}},{"id":1457035,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-10T21:01:06.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":17778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date."}],"balance_after":17778,"derivative":{"underlying":"Common Stock","underlying_shares":17778},"source":{"system":"sec-edgar","filing":"0001104659-24-078983","document":"tm2419184-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465924078983/tm2419184-2_4seq1.xml","form_type":"4"}},{"id":1457034,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":22964,"kind":"person","name":"Garfield Alastair","position":1,"cik":"0002027261","reported_name":"Garfield Alastair","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-10T21:01:06.000Z","date":"2024-07-08","kind":"grant","planned":false,"acquired":true,"shares":53333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date, as to 6.25% of the total number of shares of common stock subject to the options upon the Reporting Person's completion of each successive three months of service to the Issuer after July 1, 2024, such that the option shall be fully vested and exercisable on July 1, 2028."}],"balance_after":53333,"derivative":{"exercise_price":43.76,"expiration_date":"2034-07-07","underlying":"Common Stock","underlying_shares":53333},"source":{"system":"sec-edgar","filing":"0001104659-24-078983","document":"tm2419184-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027261/000110465924078983/tm2419184-2_4seq1.xml","form_type":"4"}}]}